Essential Pharma Acquires Reminyl Oral Capsules from Janssen Pharmaceutica
April 18, 2024
Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide) oral capsules from Janssen Pharmaceutica NV (a Johnson & Johnson company). The deal transfers rights in the EEA, South Korea, Thailand and other current markets (excluding the UK & Ireland, Japan and Latin America), expanding Essential Pharma’s CNS portfolio and its presence in the Asia‑Pacific region.
- Buyers
- Essential Pharma
- Targets
- Reminyl (galantamine hydrobromide) oral capsules
- Sellers
- Janssen Pharmaceutica NV, Johnson & Johnson
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.